Surgery on unfavourable persistent N2/N3 non-small-cell lung cancer after trimodal therapy: Do the results justify the risk?

Interactive Cardiovascular and Thoracic Surgery

Volumn 15, Issue 6, 2012, Pages 948-953

  Steger, Volker ^a,b   Walker, Tobias ^b   Mustafi, Migdat ^b   Lehrach, Karoline ^b   Kyriss, Thomas ^a   Veit, Stefanie ^a   Friedel, Godehard ^a   Walles, Thorsten ^c  

^a Schillerhöhe Hospital   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Lung cancer; Neoadjuvant therapy; Outcome; Surgery

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; VINDESINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LENGTH OF STAY; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM METASTASIS; MULTIPLE CYCLE TREATMENT; OPERATION DURATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RESIDUAL VOLUME; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL TIME; THORACOTOMY; TOTAL LUNG CAPACITY;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; HOSPITAL MORTALITY; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; NEOADJUVANT THERAPY; NEOPLASM STAGING; PATIENT SELECTION; PNEUMONECTOMY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84870152116     PISSN: 15699293     EISSN: 15699285     Source Type: Journal    
DOI: 10.1093/icvts/ivs400     Document Type: Article

References (25)

1. Call S, Rami-Porta R, Obiols C, Serra-Mitjans M, Gonzalez-Pont G, Bastus-Piulats R et al. Repeat mediastinoscopy in all its indications: experience with 96 patients and 101 procedures. Eur J Cardiothorac Surg 2011;39:1022-7.
2. Dooms C, Verbeken E, Stroobants S, Nackaerts K, De Leyn P, Vansteenkiste J. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric- pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. J Clin Oncol 2008;26:1128-34.
3. Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 2010;28:3739-45.
4. Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 2010;28:3299-306.
5. Roth JA, Atkinson EN, Fossella F, Komaki R, Bernadette Ryan M, Putnam JB et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998;21:1-6. (Pubitemid 29027851)
6. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. New Engl J Med 1994;330:153-8. (Pubitemid 24026882)
7. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT 3rd, Weick JK et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995;13:1880-92.
8. Bueno R, Richards WG, Swanson SJ, Jaklitsch MT, Lukanich JM, Mentzer SJ et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 2000;70:1826-31. (Pubitemid 32015269)
9. Betticher DC, Hsu Schmitz SF, Totsch M, Hansen E, Joss C, von Briel C et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003;21:1752-9. (Pubitemid 46638588)
10. Cerfolio RJ, Bryant AS. Restaging after neo-adjuvant chemoradiotherapy for N2 non-small cell lung cancer. Thorac Surg Clin 2008;18:417-21.
11. Paul S, Mirza F, Port JL, Lee PC, Stiles BM, Kansler AL et al. Survival of patients with clinical stage IIIA non-small cell lung cancer after induction therapy: age, mediastinal downstaging, and extent of pulmonary resection as independent predictors. J Thorac Cardiovasc Surg 2011;141:48-58.
12. Takeda S, Maeda H, Okada T, Yamaguchi T, Nakagawa M, Yokota S et al. Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer. Eur J Cardiothorac Surg 2006;30:184-9. (Pubitemid 43850324)
13. Marra A, Hillejan L, Fechner S, Stamatis G. Remediastinoscopy in restaging of lung cancer after induction therapy. J Thorac Cardiovasc Surg 2008;135:843-9. (Pubitemid 351444795)
14. Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(3 Suppl):243S-65S. (Pubitemid 47502811)
15. Alifano M, Boudaya MS, Salvi M, Collet JY, Dinu C, Camilleri-Broet S et al. Pneumonectomy after chemotherapy: morbidity, mortality, and longterm outcome. Ann Thorac Surg 2008;85:1866-72; discussion 1872-63.
16. Cerfolio RJ, Bryant AS, Jones VL, Cerfolio RM. Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non-small cell lung cancer is safe and may provide increased survival. Eur J Cardiothorac Surg 2009;35:718-23; discussion 723.
17. Edelman MJ, Suntharalingam M, Burrows W, Kwong KF, Mitra N, Gamliel Z et al. Phase I/II trial of hyperfractionated radiation and chemotherapy followed by surgery in stage III lung cancer. Ann Thorac Surg 2008;86: 903-10.
18. Friedel G, Budach W, Dippon J, Spengler W, Eschmann SM, Pfannenberg C et al. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol 2010; 28:942-8.
19. Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN Jr et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II southwest oncology group study S9504. J Clin Oncol 2003;21:2004-10. (Pubitemid 46606390)
20. Stefani A, Alifano M, Bobbio A, Grigoroiu M, Jouni R, Magdeleinat P et al. Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients. J Thorac Cardiovasc Surg 2010;140:356-63.
21. Higgins KA, Chino JP, Ready N, Onaitis MW, Berry MF, D'Amico TA et al. Persistent N2 disease after neoadjuvant chemotherapy for non-small-cell lung cancer. J Thorac Cardiovasc Surg 2011;142:1175-9.
22. Watanabe Y, Shimizu J, Oda M, Hayashi Y, Watanabe S, Iwa T. Results of surgical treatment in patients with stage IIIA non-small-cell lung cancer. Thorac Cardiovasc Surg 1991;39:44-9.
23. Fang D, Zhang D, Huang G, Zhang R, Wang L. Results of surgical resection of patients with primary lung cancer: a retrospective analysis of 1905 cases. Ann Thorac Surg 2001;72:1155-9. (Pubitemid 32937996)
24. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60. (Pubitemid 38101630)
25. Choy H, Nabid A, Stea B, Scott C, Roa W, Kleinberg L et al. Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005;23: 5918-28.